NFG
SCNI

Next Financial Group’s Scinai Immunotherapeutics SCNI Stock Holding History

Next Financial Group’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$3K Hold
14
– – ﹤0.01% 2558
2021
Q3 		$3K Hold
14
– – ﹤0.01% 2405
2021
Q2 		$4K Hold
14
– – ﹤0.01% 2274
2021
Q1 		$5K Hold
14
– – ﹤0.01% 2119
2020
Q4 		$4K Hold
14
– – ﹤0.01% 2050
2020
Q3 		$53K Buy
+14
New +$53.7K 0.01% 1087

Other funds holding SCNI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Next Financial Group's SCNI Position: Q4 2021 in Review

Next Financial Group held its Scinai Immunotherapeutics (SCNI) position steady in Q4 2021 at 14 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2558.

Next Financial Group first reported a position in SCNI in Q3 2020 and has held it in 6 quarters since. The position peaked at $53K in Q3 2020. 14 funds tracked by Wall St. Rank hold SCNI as of Q4 2021.

  • Next Financial Group held 14 shares of Scinai Immunotherapeutics worth $3K as of Q4 2021.
  • Next Financial Group left its Scinai Immunotherapeutics share count unchanged in Q4 2021.
  • Scinai Immunotherapeutics made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #2558 holding.
  • Next Financial Group first reported a position in Scinai Immunotherapeutics in Q3 2020 and has held it in 6 quarters since.
  • Next Financial Group's Scinai Immunotherapeutics position peaked at $53K in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.